Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Chishimba, R. Niven, D. Denning (Manchester, United Kingdom). Improvement in asthma severity and control by voriconazole and posaconazole in severe asthma with fungal sensitization (SAFS) and ABPA. Eur Respir J 2012; 40: Suppl. 56, 199

Member's Comments

No comment yet.

Related content which might interest you: Retrospective study on the combined use of voriconazole and prednisolone in the treatment of acute allergic bronchopulmonary aspergillosis (ABPA). Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 IgE expression in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA) Source: Annual Congress 2013 –Asthma Year: 2013 Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis Source: Eur Respir J 2014; 43: 1487-1500 Year: 2014 Prevalence of possible severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA) in a UK secondary care hospital Source: Annual Congress 2013 –Epidemiology of asthma Year: 2013 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Serum level directed itraconazole therapy in allergic bronchopulmonary aspergillosis Source: International Congress 2016 – Molecular immunology of the lung Year: 2016 Diagnostic value of combined sIgG and sIgE of Aspergillus fumigatus in allergic broncho pulmonary aspergillosis and severe asthma with fungal sensitation Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 Effect of itraconazole therapy on disease course in 3 cases of allergic bronchopulmonary mycosis presented as refractory asthma Source: Annual Congress 2008 - Allergy and immunology of asthma and beyond Year: 2008 Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Follow-up of patients with allergic bronchopulmonary aspergillosis (ABPA) - side effects of long-term therapy Source: Eur Respir J 2003; 22: Suppl. 45, 237s Year: 2003 Omalizumab is an effective intervention in severe asthma with aspergillus sensitisation. Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Fungal sensitisation in children with severe therapy resistant asthma Source: Annual Congress 2012 - Severe asthma and developing allergy in childhood Year: 2012 Bronchopulmonary aspergillosis Source: Respipedia Article Year: 2017 Itraconazole and allergic bronchopulmonary aspergillosis: long-term follow-up Source: Eur Respir J 2001; 18: Suppl. 33, 432s Year: 2001 Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006 A randomised trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmonary aspergillosis complicating asthma Source: Eur Respir J, 52 (3) 1801159; 10.1183/13993003.01159-2018 Year: 2018 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Omalizumab and voriconazole in allergic broncopulmonary aspergillosis (A case series) Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009